Clinical and Translational Allergy最新文献

{"title":"From Inflammation to Tissue State: A Compartment Model for Chronic Rhinosinusitis","authors":"Martin Desrosiers, Francois Lavigne, Leandra Mfuna Endam, Sheherazade Jannat, Audrey Pelletier","doi":"10.1002/clt2.70207","DOIUrl":"10.1002/clt2.70207","url":null,"abstract":"","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 9","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149036801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phenotypic Clusters of Severe Asthma and Response to Dupilumab in Real-World Practice","authors":"Daria S. Fomina,&nbsp;Sergey V. Fedosenko,&nbsp;Аnton А. Chernov,&nbsp;Elena N. Bobrikova,&nbsp;Оlga А. Mukhina,&nbsp;Marina S. Lebedkina,&nbsp;Alexander V. Karaulov,&nbsp;Asel Yu. Nurtazina,&nbsp;Mariana A. Lysenko,&nbsp;Harald Renz","doi":"10.1002/clt2.70198","DOIUrl":"10.1002/clt2.70198","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Severe asthma is a heterogeneous disease with variable clinical and inflammatory profiles that may influence responses to biological therapies. Identifying phenotypic clusters may help optimize patient selection and treatment outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To identify phenotypic clusters (PCs) of patients with severe asthma treated with dupilumab and to assess differences in treatment response across clusters over a 12-month period in a real-world setting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a retrospective study involving 140 adult patients with severe, poorly controlled T2-asthma who received dupilumab as first-line biological therapy for at least 12 months. Agglomerative clustering was applied to baseline clinical, laboratory, and functional parameters to identify PCs. Treatment response was assessed at 1, 6, and 12 months using ACT, ACQ-5, AQLQ, lung function (pre-bronchodilator FEV₁), T2-biomarkers, and exacerbation rates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Three phenotypic clusters were identified. PC1 (early-onset allergic asthma with high IgE and severe atopic dermatitis) and PC3 (late-onset mixed asthma with moderate IgE and persistent eosinophilia) showed rapid improvements in asthma control, lung function, and quality of life, with 71% and 75% of patients free from exacerbations, respectively. PC2 (predominantly non-allergic, late-onset, female-dominant, with CRSwNP and NSAID hypersensitivity) demonstrated slower but progressive improvement, with 61.2% remaining exacerbation-free after 12 months.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>This retrospective real-world study identified distinct phenotypic clusters of severe asthma with differential responses to dupilumab. Early identification of these phenotypes may help guide personalized asthma management.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 9","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13578103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CCR2/CCR5 Signaling Defines a Pathogenic Interstitial Macrophage Subset That Drives Severe Asthma","authors":"Hao Wang,&nbsp;Nok Him Fung,&nbsp;Christian Aloe,&nbsp;Nazanin Zounemat Kermani,&nbsp;Ian M. Adcock,&nbsp;Stavros Selemidis,&nbsp;Ross Vlahos,&nbsp;Jonathan McQualter,&nbsp;Steven Bozinovski","doi":"10.1002/clt2.70201","DOIUrl":"10.1002/clt2.70201","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Severe asthma is a chronic inflammatory disease characterised by airway dysfunction, persistent immune activation and corticosteroid resistance. While macrophages are key regulators of lung immunity, how individual subsets, particularly interstitial macrophages (IMs), contribute to disease remains poorly understood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Lung macrophages were profiled using single-cell RNA-sequencing (scRNA-seq) and flow cytometry in a C57BL/6 mouse model of severe asthma induced by Complete Freund's Adjuvant (CFA) and house dust mite (HDM). Human transcriptomic data from the U-BIOPRED asthma cohort were analyzed for translational validation. The dual CCR2/CCR5 antagonist Cenicriviroc (CVC) was used to evaluate the therapeutic potential of targeting pathogenic macrophages.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>CFA-HDM treatment led to marked depletion of resident alveolar macrophages (rAMs) and their replacement by recruited AMs (recAMs) associated with tissue remodeling. A distinct Lyve1^loMHCII^hi IM subset emerged as the dominant inflammatory cell population, displaying high <i>Ccr2</i> and <i>Ccr5</i> expression, potent pro-inflammatory and antigen-presenting signatures, and extensive ligand–receptor communication with T cells, neutrophils and rAMs. Trajectory analysis demonstrated that both recAMs and Lyve1^loMHCII^hi IMs arise from classical monocytes. Consistently, sputum transcriptomic data from the U-BIOPRED asthma cohort showed reduced AM-associated gene signatures and enrichment of IM/monocyte and CCR-chemokine programs in patients with severe disease. Pharmacological blockade of CCR2/CCR5 with CVC markedly reduced IM infiltration, limited T-cell and neutrophil recruitment, restored macrophage balance, and improved lung function.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Lyve1^loMHCII^hi IMs orchestrate airway inflammation in severe asthma. Dual CCR2/CCR5 antagonism inhibits their recruitment, restores macrophage balance, and halts disease progression, highlighting this pathway as a promising therapeutic target.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 9","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13570780/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Artificial Intelligence-Based Platforms to Support Searches in Evidence Synthesis Studies: A Study of the EAACI Methodology Committee","authors":"Bernardo Sousa-Pinto,&nbsp;Antonio Bognanni,&nbsp;Paweł Jemioło,&nbsp;Rafael José Vieira,&nbsp;Thinh H. Nguyen,&nbsp;Zachary Munn,&nbsp;Timothy Hugh Barker,&nbsp;Lemma N. Bulto,&nbsp;Danilo di Bona,&nbsp;Jean Bousquet,&nbsp;Mário Dinis-Ribeiro,&nbsp;João A. Fonseca,&nbsp;Mariette Awad,&nbsp;Manuel Marques-Cruz,&nbsp;Holger J. Schünemann","doi":"10.1002/clt2.70202","DOIUrl":"https://doi.org/10.1002/clt2.70202","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To demonstrate an evaluation of the use of artificial intelligence (AI) in supporting tasks in evidence synthesis (particularly search for primary studies) in the allergy or respirology fields.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We queried three AI-based platforms specialised on identifying scientific publications using several strategies (i.e., prompting strategies and search approaches) in November 2024 to identify primary studies related to health-related case studies in the allergy or respirology field. We compared how many eligible primary studies we identified using AI-based platforms versus in a systematic search in multiple electronic bibliographic databases. We also compared meta-analytical results obtained with the primary studies identified by querying AI-based platforms versus in the context of a systematic review. Finally, we developed a structured methodological framework and a reporting checklist for using these AI-based platforms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In our main case study, a systematic review of randomised controlled trials (RCTs) informing the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, a strategy involving searching multiple AI-based platforms identified 85.7% of all full articles with DOI, but failed to identify unpublished trials registered in trial databases, resulting in an overall identification of 56.3% eligible RCTs. Meta-analytical estimates were similar when considering only the primary studies identified using AI-based strategies versus those identified by the systematic review. We observed a lower performance in the case study of systematic reviews of observational studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We provide an example on how it is possible to evaluate AI-based platforms in the support of evidence synthesis, with a focus on the allergy and respirology fields.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 9","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70202","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148943186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “New Insights Into Immunomodulatory Strategies for Drug Hypersensitivity Reactions: An EAACI Task Force Report”","authors":"","doi":"10.1002/clt2.70199","DOIUrl":"10.1002/clt2.70199","url":null,"abstract":"<p>A. M. Copaescu, V. Gueli, J. Chahuan, et al., “New Insights Into Immunomodulatory Strategies for Drug Hypersensitivity Reactions: An EAACI Task Force Report,” <i>Clinical and Translational Allergy</i> (2026): e70195, https://doi.org/10.1002/clt2.70195.</p><p>In the author list, the name of one of the co-authors was published incorrectly as “Jitesh Chahuan”. The correct author name is “Jitesh Chauhan”. This error has been corrected.</p><p>We apologize for this error.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 9","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13550521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148904573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Efficacy and Systemic Immune Modulation Upon Tralokinumab Treatment in Atopic Dermatitis","authors":"Meslina Almaci,&nbsp;Philipp Globig,&nbsp;Davender Redhu,&nbsp;Margitta Worm","doi":"10.1002/clt2.70200","DOIUrl":"10.1002/clt2.70200","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Tralokinumab, an interleukin-13 (IL-13) monoclonal antibody, has shown clinical efficacy in randomized trials for moderate-to-severe atopic dermatitis (AD). This study aims to evaluate clinical and immunological outcome upon tralokinumab treatment in a real-world cohort of patients with moderate-to-severe AD.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We recruited 81 AD patients receiving tralokinumab, performing clinical assessments (oScorad, IGA, BSA, DLQI, pruritus-VAS) at baseline and months 3, 6, 9, and 12. For immunophenotyping (<i>n</i> = 25), PBMCs were collected at baseline and months 6/12. Peripheral T-cell subsets, CLA, OX40, TFH, and cytokines (IL-4, IL-13, IL-17A, IL-10, IFNγ) were analyzed via multiparametric flow cytometry. Serum total/specific IgEs were measured by ImmunoCap and eosinophils by differential blood counts.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Tralokinumab treatment induced a continued clinical response: at 12 months, oScorad and BSA decreased by 60.8% and 78.8%. CLA⁺CD4⁺ and CD8⁺ T cells declined by 63.0% and 25.8%, and OX40⁺ CD4⁺/CD8⁺ T cells by 62.4% and 44.0%. CD4⁺ effector memory T cells increased 4.6-fold, while TEMRA cells decreased 34.0%. CD4⁺ T cells expressing IL-13, IL-4, and IL-17A declined by 70.8%, 72.8%, and 69.3%, while IFNγ⁺ and IL-10⁺ CD4⁺ T cells increased by 62.0%. Total IgE decreased by 9.7%, while eosinophil counts remained stable.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In real-world practice, tralokinumab achieves robust clinical benefit and a rebalanced systemic immune pattern. Selective IL-13 blockade reshapes T-cell function, shifting the immune balance from Th2/Th17 dominance toward Th1/regulatory profiles, suggesting immunomodulatory effects consistent with disease modification. Future studies are needed to determine the long-term stability of these immunological changes following treatment prolongation or interruption.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 9","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13547590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148900106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Why Is the Prevention of Passive Transport of Cat Allergens So Important in Clinical Practice?","authors":"Gennaro Liccardi,&nbsp;Matteo Martini,&nbsp;Maria Beatrice Bilò,&nbsp;Lorenzo Cecchi,&nbsp;Manlio Milanese,&nbsp;Roberta Maniscalco,&nbsp;Paola Rogliani","doi":"10.1002/clt2.70197","DOIUrl":"https://doi.org/10.1002/clt2.70197","url":null,"abstract":"&lt;p&gt;To the Editor&lt;/p&gt;&lt;p&gt;We read with interest the article of Colosimo et al. [&lt;span&gt;1&lt;/span&gt;] concerning innovative strategies to reduce exposure and consequent allergic sensitization to cat allergen Fel d 1.&lt;/p&gt;&lt;p&gt;The article is very complete, and we have no objections to its contents. However, we wish to address an additional and universal exposure pathway that is the passive transport of cat allergens in animal-free environments and, above all, the lack of information on preventive measures to this crucial aspect.&lt;/p&gt;&lt;p&gt;This clarification is important because the majority of the innovative strategies reported in the text are applicable just to the single cat that is owned by the patient, or to the indoor environment where the animal lives. Obviously, patients remain exposed to the allergens/environments of other cats that they may encounter. On the contrary, targeted prevention measures against passive transport have a universal character as they should reduce the phenomenon of the “ubiquity” of the cat allergen and therefore the risk of sensitization without contact with animals.&lt;/p&gt;&lt;p&gt;Cat (and dog) allergens should be considered as ubiquitous because they are found not only in indoor environments where these animals are kept, but also in other indoor private or public places where they have never been kept. Public spaces include nurseries, offices, hospitals, hotels, schools and means of public transport. These indoor environments, contaminated by cat allergens, are able to induce allergic sensitization in susceptible individuals and trigger respiratory symptoms in already highly sensitized subjects. In fact, in these contaminated environments, the amount of cat allergens is higher than clinically significant thresholds. Namely, 1 and 8–10 μg of allergen/g are generally recognized as sufficient to induce sensitization or trigger respiratory symptoms for dust, respectively. Obviously, these thresholds must be considered as “averages” over the population examined in clinical studies. However, in clinical practice, it is necessary to account the wide individual susceptibility to pet allergen exposure resulting from genetic and environmental factors, as these variables are able of influencing the onset of more or less severe symptoms.&lt;/p&gt;&lt;p&gt;In developed countries, the cat allergen ubiquity causes a persistent stimulation of airways like that induced by dust mite.&lt;/p&gt;&lt;p&gt;Accumulation of cat allergens in indoor environments without animals is correlated with the number of visitors owning a cat or with those who are in regular contact with these animals. We have shown that clothing [&lt;span&gt;2&lt;/span&gt;], but also human hair [&lt;span&gt;3&lt;/span&gt;], constitute a means of transferring cat allergens into pet-free indoor environments (Figure 1).&lt;/p&gt;&lt;p&gt;We have previously demonstrated it in a less common pet (rabbit) [&lt;span&gt;5&lt;/span&gt;]. However, a smaller body of evidence suggests the possibility of passive transport of allergens also in other animals such as horses [&lt;s","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 9","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70197","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148872064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ARIA-EAACI 2025: Person-Centred, Digitally Enabled and Artificial Intelligence-Assisted Change Management in Airway Diseases","authors":"Jean Bousquet,&nbsp;Bernardo Sousa-Pinto,&nbsp;Mohamed H. Shamji,&nbsp;Maria J. Torres,&nbsp;Ludger Klimek,&nbsp;Holger J. Schünemann,&nbsp;Mario Morais-Almeida,&nbsp;Rafael José Vieira,&nbsp;Alkis Togias,&nbsp;Boleslaw Samolinski,&nbsp;Arunas Valiulis,&nbsp;Siân Williams,&nbsp;Oliver Pfaar,&nbsp;Torsten Zuberbier,&nbsp;Anna Bedbrook,&nbsp;Wienczyslawa Czarlewski,&nbsp;Maryam Ali Al-Nesf,&nbsp;Rita Amaral,&nbsp;Josep M. Anto,&nbsp;Antonio Bognanni,&nbsp;Luisa Brussino,&nbsp;Alvaro A. Cruz,&nbsp;Violeta Kvedariene,&nbsp;Habib Douagui,&nbsp;Nikolaos G. Papadopoulos,&nbsp;G. Walter Canonica,&nbsp;Ivan Cherrez-Ojeda,&nbsp;Mark Dykewicz,&nbsp;Bilun Gemicioglu,&nbsp;Mattia Giovannini,&nbsp;Brigita Gradauskiene,&nbsp;Tari Haahtela,&nbsp;Cristina Jacomelli,&nbsp;Tuomas Jartti,&nbsp;Miloš Jeseňák,&nbsp;Piotr Kuna,&nbsp;Désirée E. Larenas-Linnemann,&nbsp;Amir H. A. Latiff,&nbsp;Bryan Martin,&nbsp;Yousser Mohammad,&nbsp;Kari Nadeau,&nbsp;Elizabete Nunes,&nbsp;Ken Ohta,&nbsp;Martial Ouédraogo,&nbsp;Padukudru A. Mahesh,&nbsp;Isabella Pali-Schölll,&nbsp;Ana Margarida Pereira,&nbsp;Frederico S. Regateiro,&nbsp;Nicolas Roche,&nbsp;Mikhail Sofiev,&nbsp;Luis Taborda-Barata,&nbsp;Charlotte Suppli Ulrik,&nbsp;Sanna K. Toppila-Salmi,&nbsp;Marylin Valentin Rostan,&nbsp;Leticia de las Vecillas,&nbsp;Maria Teresa Ventura,&nbsp;Giovanni Viegi,&nbsp;De Yun Wang,&nbsp;He Zhang,&nbsp;Luo Zhang,&nbsp;Giorgio Ciprandi,&nbsp;Juan Carlos Ivancevich,&nbsp;Nikolai Khaltaev,&nbsp;Olga Lourenço,&nbsp;Lucas Leemann,&nbsp;Marine Savouré,&nbsp;Juan Jose Yepes-Nuñez,&nbsp;Arzu Yorgancioglu,&nbsp;Baharudin Abdullah,&nbsp;Mona Al-Ahmad,&nbsp;Julijana Asllani,&nbsp;Karl-C. Bergmann,&nbsp;Jonathan A. Bernstein,&nbsp;Michael S. Blaiss,&nbsp;Fulvio Braido,&nbsp;Pedro Carreiro-Martins,&nbsp;Lorenzo Cecchi,&nbsp;Antonio F. M. Giuliano,&nbsp;George Christoff,&nbsp;Ieva Cirule,&nbsp;Jaime Correia-de-Sousa,&nbsp;Elisio M. Costa,&nbsp;Biljana Cvetkovski,&nbsp;Stefano Del Giacco,&nbsp;Philippe Devillier,&nbsp;Dejan Dokic,&nbsp;Maia Gotua,&nbsp;Maria Antonieta Guzman,&nbsp;Elham Hossny,&nbsp;Tomohisa Iinuma,&nbsp;Carla Irani,&nbsp;Zhanat Ispayeva,&nbsp;Kaja Julge,&nbsp;Igor Kaidashev,&nbsp;Kazi S. Bennoor,&nbsp;Helga Kraxner,&nbsp;Inger Kull,&nbsp;Marek Kulus,&nbsp;Maciej Kupczyk,&nbsp;Andriy Kurchenko,&nbsp;Xin Luo,&nbsp;Stefania La Grutta,&nbsp;Lan Le Thi Tuyet,&nbsp;Michael Makris,&nbsp;Branislava Milenkovic,&nbsp;Neven Miculinic,&nbsp;Sang Min Lee,&nbsp;Stephen Montefort,&nbsp;André Moreira,&nbsp;Joaquim Mullol,&nbsp;Rachel Nadif,&nbsp;Alla Nakonechna,&nbsp;Hugo E. Neffen,&nbsp;Stefania Nicola,&nbsp;Marek Niedoszytko,&nbsp;Dieudonné Nyembue,&nbsp;Robyn E. O’Hehir,&nbsp;Ismail Ogulur,&nbsp;Yoshitaka Okamoto,&nbsp;Markus Ollert,&nbsp;Heidi Olze,&nbsp;Oscar Palomares,&nbsp;Petr Panzner,&nbsp;Hae-Sim Park,&nbsp;Vincenzo Patella,&nbsp;Ruby Pawankar,&nbsp;Constantinos Pitsios,&nbsp;Todor A. Popov,&nbsp;Francesca Puggioni,&nbsp;Santiago Quirce,&nbsp;Agné Ramonaité,&nbsp;Marysia Recto,&nbsp;Maria Susana Repka-Ramirez,&nbsp;Karla Robles-Velasco,&nbsp;Menachem Rottem,&nbsp;Marianella Salapatas,&nbsp;Joaquin Sastre,&nbsp;Nicola Scichilone,&nbsp;Juan-Carlos Sisul,&nbsp;Dirceu Solé,&nbsp;Manuel Soto-Martinez,&nbsp;Milan Sova,&nbsp;Katarina Stevanovic,&nbsp;Pongsakorn Tantilipikorn,&nbsp;Ana Todo-Bom,&nbsp;Vladyslav Tsaryk,&nbsp;Ioanna Tsiligianni,&nbsp;Marilyn Urrutia-Pereira,&nbsp;Erkka Valovirta,&nbsp;Tuula Vasankari,&nbsp;Dana Wallace,&nbsp;Margitta Worm,&nbsp;Osman M. Yusuf,&nbsp;Fares Zaitoun,&nbsp;Mihaela Zidarn,&nbsp;ARIA study group","doi":"10.1002/clt2.70192","DOIUrl":"https://doi.org/10.1002/clt2.70192","url":null,"abstract":"<p>Allergic Rhinitis and its Impact on Asthma (ARIA) was, up until 2017, a guideline using the best evidence (Grading of Recommendations, Assessment, Development and Evaluation, GRADE) and developed as a change management strategy. A second change management strategy—in collaboration with the European Academy of Allergy and Clinical Immunology (ARIA-EAACI)—was developed as a person-centred, digitally enabled, artificial intelligence-assisted care (person-centred care) with strong political involvement. The digital tools of ARIA are mainly based on MASK-air, an Organisation for Economic Co-operation and Development (OECD) Best Practice for integrated care for chronic diseases. Artificial intelligence was used, in particular, to approach the patients' views and expectations. The current paper describes the steps to build and achieve a new change management strategy. The future of the Change Management strategy is (i) a collaboration between ARIA and EAACI, (ii) the development of ARIA 2024-2025 guidelines, (iii) the new ARIA-MeDALL classification of multimorbid airway diseases and (iv) embedding MASK-air in a registry for severe allergic diseases. The ultimate goals of the ARIA-EAACI change management strategy will be (i) the transformation of health and care in rhinitis and asthma multimorbidity and (ii) the development of novel guidelines and policies in a cost-effective manner, improving shared-decision-making.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 8","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70192","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148783945","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Berotralstat Tolerability and Effectiveness in Hereditary Angioedema: Berolife Study Results","authors":"Delphine Gobert,&nbsp;David Launay,&nbsp;Isabelle Boccon-Gibod,&nbsp;Melisande Bourgoin-Heck,&nbsp;Cyrille Hoarau,&nbsp;Yann Ollivier,&nbsp;Hervé Maillard,&nbsp;Fabien Pontille,&nbsp;Nicolas Ozanne,&nbsp;Magali Aubineau,&nbsp;Claire de Moreuil,&nbsp;Anne Gerber,&nbsp;Fabien Pelletier,&nbsp;Pierre-Yves Jeandel,&nbsp;Aurélie Du-Thanh,&nbsp;Marie-Caroline Dalmas,&nbsp;Marie-Caroline Taquet,&nbsp;Jean Schmidt,&nbsp;Amélie Servettaz,&nbsp;Amandine Perier,&nbsp;Enzo Cohen,&nbsp;Laure Carriat,&nbsp;Nicolas Lemaire,&nbsp;Mona Villedieu,&nbsp;Jean-Charles Crave,&nbsp;Olivier Fain,&nbsp;Laurence Bouillet","doi":"10.1002/clt2.70193","DOIUrl":"10.1002/clt2.70193","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Berotralstat is a first-line once-daily oral prophylactic treatment for hereditary angioedema (HAE). Berolife was designed to evaluate the tolerability and effectiveness of berotralstat in real-world conditions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Berolife is an open-label, multicenter, observational study conducted in France from September 2021 to January 2024. The primary objective was to assess tolerability, and secondary objectives included characterization of the treated population and assessment of berotralstat effectiveness. HAE attack rate was assessed before and after initiation of berotralstat using the paired Wilcoxon rank-sum test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Altogether, 80 patients were enrolled in the study (75 with HAE-C1INH type 1 or 2 and 5 with HAE-nC1INH) and received at least one dose of berotralstat. At baseline, patients had a mean (standard deviation [SD]) age of 40.0 (17.5) years, and most (67.5%) had received prior long-term prophylaxis treatment. The mean (SD) duration of berotralstat treatment was 11.5 (8.5) months. Treatment-related adverse events (AEs) occurred in 45.0% of patients, with gastrointestinal disorders being the most common (diarrhea: 13.8%, abdominal pain: 12.5%, upper abdominal pain: 7.5%). Importantly, no treatment-related serious AEs were reported. A total of 61 patients were treated with berotralstat for ≥ 6 months and evaluated for effectiveness. At 6 months of treatment, a significant reduction in monthly HAE attack rates was observed (mean [SD]: 0.62 [0.66] vs. mean [SD]: 1.25 [1.10] at baseline; <i>p</i> = 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Berotralstat was generally well tolerated with a tolerability profile consistent with prior clinical trials. Significant reductions in monthly HAE attack rates were observed, confirming its effectiveness in real-world settings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 8","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13477265/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148758807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Insights Into Immunomodulatory Strategies for Drug Hypersensitivity Reactions: An EAACI Task Force Report","authors":"Ana Maria Copaescu,&nbsp;Valentina Gueli,&nbsp;Jitesh Chahuan,&nbsp;Waad Albalawi,&nbsp;Giovanna Sfriso,&nbsp;Mattia Giovannini,&nbsp;Leticia de las Vecillas,&nbsp;Aspasia Karavelia,&nbsp;Marina Labella,&nbsp;Ruben Fernandez-Santamaria,&nbsp;Francesca Mori,&nbsp;Lene H. Garvey,&nbsp;Patrizia Bonadonna,&nbsp;Maria Jose Torres","doi":"10.1002/clt2.70195","DOIUrl":"https://doi.org/10.1002/clt2.70195","url":null,"abstract":"<p>Drug hypersensitivity reactions (DHRs) are a global health concern and remain challenging to investigate owing to the heterogeneity of endotypes and phenotypes, as well as the lack of standardized biomarkers. Until recently, strict drug avoidance was the only management strategy for severe DHRs. However, the development of novel therapeutic options, including biologics and drug desensitization protocols, has shown promising results, particularly when no alternatives exist. In parallel, the search for reliable biomarkers for diagnosis and monitoring immunomodulatory strategies is essential to improve patient care. Advances in the algorithms and digital tools also offer opportunities for enhanced risk stratification and more efficient delabeling of patients who may be incorrectly classified as allergic. In this review, we summarize recent advances in the classification of DHRs, discuss current and emerging immunomodulatory strategies for their management, and highlight relevant biomarkers, emphasizing the need to integrate them into clinical practice.</p>","PeriodicalId":10334,"journal":{"name":"Clinical and Translational Allergy","volume":"16 8","pages":""},"PeriodicalIF":4.2,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clt2.70195","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148753453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}